ELAN

+ Watchlist + Portfolio

Elanco Animal Health Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $24.50
52-Week Range: $17.11 – $27.98
Market Cap: $11.77B
P/E (TTM): —
EPS (TTM): -0.41
Dividend Yield: —

Advanced Metrics

Price/Book: 1.79
PEG Ratio: 4.04
Return on Equity: -2.98%
Return on Assets: 1.56%
Gross Margin: 55.36%
Operating Margin: 8.63%
Profit Margin: -3.96%
Current Ratio: 2.05
Debt/Equity: 0.64
Total Debt: $4.23B
Free Cash Flow: $826.88M
Revenue Growth: 10.20%
Earnings Growth: 440.50%
Enterprise Value: $15.94B

ELAN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$4.41B	$4.42B	$4.44B	$4.71B
Cost of Revenue	$1.91B	$1.93B	$2.00B	$2.12B
Gross Profit	$2.50B	$2.49B	$2.44B	$2.59B
Research & Development	$321.00M	$327.00M	$344.00M	$368.00M
Selling, General & Admin	$1.26B	$1.28B	$1.31B	$1.43B
Operating Expenses	$2.11B	$2.16B	$2.19B	$2.34B
Operating Income	$384.00M	$326.00M	$251.00M	$252.00M
EBITDA	$851.00M	-$224.00M	$1.39B	$676.00M
Pretax Income	-$72.00M	-$1.20B	$488.00M	-$224.00M
Income Tax	$6.00M	$36.00M	$150.00M	$8.00M
Net Income	-$78.00M	-$1.23B	$338.00M	-$232.00M
Diluted EPS	-0.15	-2.50	0.68	-0.47
Diluted Shares	488.30M	492.30M	497.30M	496.40M

ELAN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$345.00M	$352.00M	$468.00M	$545.00M
Receivables	$1.00B	$1.01B	$886.00M	$940.00M
Inventory	$1.54B	$1.74B	$1.57B	$1.74B
Current Assets	$3.28B	$3.41B	$3.21B	$3.46B
Total Assets	$15.49B	$14.36B	$12.61B	$13.36B
Current Liabilities	$1.70B	$1.24B	$1.31B	$1.60B
Long-Term Debt	$5.45B	$5.74B	$4.28B	$3.94B
Total Debt	$5.84B	$5.77B	$4.32B	$4.02B
Total Liabilities	$8.20B	$8.14B	$6.52B	$6.81B
Retained Earnings	-$1.06B	-$2.29B	-$1.95B	-$2.18B
Shareholders' Equity	$7.29B	$6.22B	$6.10B	$6.55B
Working Capital	$1.58B	$2.17B	$1.90B	$1.86B
Net Debt	$5.49B	$5.42B	$3.85B	$3.47B

ELAN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$452.00M	$271.00M	$541.00M	$560.00M
Capital Expenditure	-$184.00M	-$140.00M	-$147.00M	-$276.00M
Free Cash Flow	$268.00M	$131.00M	$394.00M	$284.00M
Depreciation & Amortisation	$682.00M	$694.00M	$662.00M	$680.00M
Stock-Based Compensation	$59.00M	$46.00M	$55.00M	$68.00M
Investing Cash Flow	-$179.00M	-$169.00M	$1.16B	-$279.00M
Financing Cash Flow	-$549.00M	-$83.00M	-$1.49B	-$275.00M
Net Change in Cash	-$276.00M	$19.00M	$207.00M	$6.00M

ELAN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$1.19B	$1.24B	$1.14B	$1.14B	$1.37B
Cost of Revenue	$509.00M	$528.00M	$530.00M	$555.00M	$586.00M
Gross Profit	$684.00M	$713.00M	$607.00M	$589.00M	$785.00M
Research & Development	$94.00M	$92.00M	$89.00M	$93.00M	$97.00M
Selling, General & Admin	$341.00M	$400.00M	$351.00M	$338.00M	$381.00M
Operating Expenses	$563.00M	$628.00M	$580.00M	$570.00M	$616.00M
Operating Income	$121.00M	$85.00M	$27.00M	$19.00M	$169.00M
EBITDA	$261.00M	$242.00M	$178.00M	-$5.00M	$316.00M
Pretax Income	$60.00M	$25.00M	-$50.00M	-$259.00M	$87.00M
Income Tax	-$7.00M	$14.00M	-$16.00M	$17.00M	$30.00M
Net Income	$67.00M	$11.00M	-$34.00M	-$276.00M	$57.00M
Diluted EPS	0.13	0.02	-0.07	-0.56	0.11
Diluted Shares	499.10M	500.10M	496.80M	496.90M	506.00M

ELAN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$487.00M	$539.00M	$505.00M	$545.00M	$428.00M
Receivables	$1.06B	$1.10B	$975.00M	$940.00M	$1.15B
Inventory	$1.59B	$1.67B	$1.71B	$1.74B	$1.72B
Current Assets	$3.44B	$3.61B	$3.49B	$3.46B	$3.58B
Total Assets	$12.94B	$13.74B	$13.55B	$13.36B	$13.22B
Current Liabilities	$1.27B	$1.39B	$1.46B	$1.60B	$1.66B
Long-Term Debt	$4.35B	$4.15B	$3.96B	$3.94B	$3.92B
Total Debt	$4.39B	$4.21B	$4.02B	$4.02B	$3.99B
Total Liabilities	$6.59B	$6.97B	$6.80B	$6.81B	$6.72B
Retained Earnings	-$1.88B	-$1.87B	-$1.91B	-$2.18B	-$2.13B
Shareholders' Equity	$6.35B	$6.78B	$6.75B	$6.55B	$6.50B
Working Capital	$2.17B	$2.22B	$2.04B	$1.86B	$1.92B
Net Debt	$3.91B	$3.67B	$3.52B	$3.47B	$3.56B

ELAN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.00M	$237.00M	$219.00M	$108.00M	$13.00M
Capital Expenditure	-$65.00M	-$57.00M	-$92.00M	-$62.00M	-$51.00M
Free Cash Flow	-$69.00M	$180.00M	$127.00M	$46.00M	-$38.00M
Depreciation & Amortisation	$161.00M	$169.00M	$176.00M	$174.00M	$172.00M
Stock-Based Compensation	$15.00M	$20.00M	$17.00M	$16.00M	$21.00M
Investing Cash Flow	-$58.00M	-$56.00M	-$101.00M	-$64.00M	-$60.00M
Financing Cash Flow	$52.00M	-$156.00M	-$153.00M	-$18.00M	-$65.00M
Share Repurchases	-$13.00M	—	—	—	-$34.00M
Net Change in Cash	-$10.00M	$25.00M	-$35.00M	$26.00M	-$112.00M

Market Snapshot

About

Elanco Animal Health is a global leader in animal health developing products and services to prevent and treat disease in farm animals and pets. The company offers a diverse portfolio of products including parasiticides, vaccines, antibiotics, other pharmaceuticals and nutritional supplements for livestock and companion animals. Elanco operates in more than 90 countries serving veterinarians, pet owners and livestock producers. The company was spun off from Eli Lilly and Company in 2018 and has since expanded through acquisitions including Bayer's animal health business.